These products are not FDA approved
San Diego, CA (PRWEB) July 04, 2014
AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Injectable Vitamin Products.
The FDA warned on June 30, that injectable vitamin drug products labeled “Sunshine Labs” and distributed by Medical Supply Liquidators are not FDA approved and all lots are recalled. The specific products, marketed as prescription injectable nutritional supplements, are distributed by Medical Supply Liquidators, LLC with “Sunshine Labs” on the label and are manufactured by Compound Brothers Dominicana (or CB Inc.) in the Dominican Republic.
These products are not FDA approved and the Agency cannot be assured of their quality, effectiveness, and safety.
Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds “We are determined to keep an eye on FDA announcements concerning Injectable Vitamin Products and inform the public. For that reason", he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”
As the FDA recommends “Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.”
AttorneyOne.com has further information on Injectable Vitamin Products at the website including latest major drug and medical products law news.
Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/07/prweb11994614.htm